SLN

Silence Therapeutics (SLN)

About Silence Therapeutics (SLN)

Silence Therapeutics Plc engages in the discovery, delivery, and development of ribonucleic acid (RNA) therapeutics. It also develops medicines by harnessing the body's natural mechanism of RNA interference within its cells. The company was founded on November 18, 1994 and is headquartered in London, the United Kingdom.

Details

Daily high

$6.72

Daily low

$6.20

Price at open

$6.54

52 Week High

$8.08

52 Week Low

$1.97

Market cap

311.7M

Dividend yield

0.00%

Volume

335,676

Avg. volume

317,780

P/E ratio

-3.95

Silence Therapeutics News